Clinical trials · Ohio
Carcinoma clinical trials in Ohio
We’re tracking 272 recruiting carcinoma studies with a site in Ohio — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Canton, OhioAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Canton, OhioAges 18 years+ - NCT05673148RecruitingPhase 2
Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer
This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.
Centerville, OhioAges 18 years+ - NCT05630794RecruitingPhase 1
Safety study of ONC201 for preventing colon polyps
This trial tests a drug called ONC201 to see if it can safely help prevent colon polyps from coming back in people at high risk. You will take the drug for about 12 weeks and have a second colonoscopy to check results.
Cleveland, OhioAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Columbus, OhioAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Canton, OhioAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Columbus, OhioAges 18 years+ - NCT05486572Recruiting
Ultrasound or MRI to help prevent liver cancer deaths
This study compares ultrasound scans versus MRI scans to see which one better helps prevent deaths from liver cancer in people with cirrhosis. You may be assigned to one of the two imaging tests and follow-up visits to track whether liver cancer develops or is caught early.
Cleveland, OhioAges 18–75 - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Cleveland, OhioAges 18 years+ - NCT05379153RecruitingPhase 3
Laser therapy for vaginal dryness in breast cancer survivors
This trial tests whether laser therapy can help women who have had breast cancer and now experience vaginal dryness. It aims to see if this treatment can reduce dryness and improve comfort.
Columbus, OhioAges 22 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Kettering, OhioAges 18 years+ - NCT05008848RecruitingPhase 3
Text-based quit smoking program for rural cancer survivors
This trial tests a text message program to help people who have had cancer quit smoking. It is designed for those living in rural areas and aims to see if this program can support them in stopping smoking.
Belpre, OhioAges 18 years+ - NCT04949464Recruiting
Smoking quit coaching plus lung scans for people with HIV
This study tests a behavior-change program to help people with HIV quit smoking, along with routine low-dose lung CT scans to find warning signs early. It’s a feasibility study, meaning the main goal is to see if the approach is practical and acceptable, and if people can follow through.
Columbus, OhioAges 45–80 - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Columbus, OhioAges 18 years+ - NCT04892173RecruitingPhase 3
Radiation plus a tumor injection, with or without cetuximab
This trial studies whether adding a special drug given directly into a head-and-neck tumor during radiation can improve outcomes. It also looks at whether cetuximab (an antibody medicine) should be added for people who cannot or should not have certain standard chemotherapy.
Cincinnati, OhioAges 60 years+ - NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+ - NCT04684368RecruitingPhase 2
New treatment for children and young adults with a brain tumor
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
Cleveland, OhioAges 3–29 - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
Middleburg Heights, OhioAges 18 years+ - NCT04633239RecruitingPhase 1
Testing abemaciclib plus olaparib for recurrent ovarian cancer
This Phase 1 trial studies whether adding abemaciclib to olaparib can treat women with recurrent platinum-resistant ovarian cancer. It aims to find a safe dose and see how well the combination can control the cancer.
Columbus, OhioAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Centerville, OhioAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Cincinnati, OhioAges 18 years+ - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Canton, OhioAges 18 years+ - NCT04251052Recruiting
Compare two surgeries to lower ovarian cancer risk in BRCA1 carriers
This study compares two risk-reducing surgery plans for people with a BRCA1 genetic change to see which approach helps lower ovarian cancer risk. You may be asked to have the study procedure sooner or later depending on your chosen plan.
Alliance, OhioAges 35–50 - NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Cleveland, OhioAges 18 years+
Where these studies are running in Ohio
Institutions with a site for the recruiting carcinoma studies listed above.
- The Ohio State University · 8 studies
- Atrium Medical Center · 5 studies
- Miami Valley Cancer Care and Infusion · 5 studies
- Miami Valley Hospital · 5 studies
- Miami Valley Hospital South · 5 studies
- ProMedica Flower Hospital · 5 studies
- Upper Valley Medical Center · 5 studies
- Dayton Physician LLC - Englewood · 4 studies
What taking part in a carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Carcinoma trials in other states
Common questions
- Are there carcinoma clinical trials in Ohio?
- Yes. We're currently tracking 272 recruiting carcinoma studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a carcinoma study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New carcinoma studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.